 | • レポートコード：MRC2312MG01571 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、79ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥468,000 (USD3,250) | ▷ お問い合わせ |
| Multi User | ￥608,400 (USD4,225) | ▷ お問い合わせ |
| Enterprise User | ￥702,000 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Global Recombinant Influenza Vaccine Market 調査レポートは次の情報を含め、グローバルにおけるの組換えインフルエンザワクチン市場規模と予測を収録しています。 ・世界の組換えインフルエンザワクチン市場：売上、2018年-2023年、2024年-2029年 ・世界の組換えインフルエンザワクチン市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の組換えインフルエンザワクチン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「バイアル」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。 組換えインフルエンザワクチンのグローバル主要企業は、Sanofiなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 マーケットモニターグローバル社は、組換えインフルエンザワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別マーケット分析】 世界の組換えインフルエンザワクチン市場：タイプ別、2018年-2023年、2024年-2029年 世界の組換えインフルエンザワクチン市場：タイプ別市場シェア、2022年 ・バイアル、充填済み 世界の組換えインフルエンザワクチン市場：用途別、2018年-2023年、2024年-2029年 世界の組換えインフルエンザワクチン市場：用途別市場シェア、2022年 ・公共、民間 世界の組換えインフルエンザワクチン市場：地域・国別、2018年-2023年、2024年-2029年 世界の組換えインフルエンザワクチン市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競争分析】 また、当レポートは主要な参入企業の分析を提供します。 ・主要企業における組換えインフルエンザワクチンのグローバル売上、2018年-2023年 ・主要企業における組換えインフルエンザワクチンのグローバル売上シェア、2022年 ・主要企業における組換えインフルエンザワクチンのグローバル販売量、2018年-2023年 ・主要企業における組換えインフルエンザワクチンのグローバル販売量シェア、2022年 さらに、当レポートは主要企業の情報を提示します。 Sanofi ************************************************************* ・調査・分析レポートの概要 組換えインフルエンザワクチン市場の定義 市場セグメント 世界の組換えインフルエンザワクチン市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の組換えインフルエンザワクチン市場規模 世界の組換えインフルエンザワクチン市場規模：2022年 VS 2029年 世界の組換えインフルエンザワクチン市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの組換えインフルエンザワクチンの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の組換えインフルエンザワクチン製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：バイアル、充填済み 組換えインフルエンザワクチンのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：公共、民間 組換えインフルエンザワクチンの用途別グローバル売上・予測 ・地域別市場分析 地域別組換えインフルエンザワクチン市場規模 2022年と2029年 地域別組換えインフルエンザワクチン売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど） Sanofi ... |
This research report provides a comprehensive analysis of the Recombinant Influenza Vaccine market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Recombinant Influenza Vaccine market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Recombinant Influenza Vaccine, challenges faced by the industry, and potential opportunities for market players.
The global Recombinant Influenza Vaccine market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Recombinant Influenza Vaccine market presents opportunities for various stakeholders, including Public Sector, Private Sector. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Recombinant Influenza Vaccine market. Additionally, the growing consumer demand present avenues for market expansion.
The global Recombinant Influenza Vaccine market was valued at US$ 100.7 million in 2022 and is projected to reach US$ 182.2 million by 2029, at a CAGR of 8.9% during the forecast period.
A significant driver in the Influenza Vaccine market is the growing awareness of the importance of vaccination in preventing seasonal and pandemic influenza outbreaks. As healthcare organizations and governments worldwide promote vaccination as a crucial public health measure, there is an increasing demand for influenza vaccines. Additionally, advances in vaccine research and development, including the production of more effective and broader-spectrum vaccines, are driving market growth. One of the key challenges in this market is the need for frequent vaccine updates to match evolving influenza strains. The virus undergoes genetic changes, requiring annual adjustments to vaccine formulations. This presents logistical challenges for manufacturers in terms of timely production and distribution. Vaccine hesitancy and misinformation also pose challenges by impacting vaccination rates and public perception. Lastly, ensuring equitable access to vaccines, especially in low-income and underserved populations, remains a persistent challenge in the fight against influenza.
Key Features:
The research report on the Recombinant Influenza Vaccine market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Recombinant Influenza Vaccine market.
Market Overview: The report provides a comprehensive overview of the Recombinant Influenza Vaccine market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Vial, Prefilled), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Recombinant Influenza Vaccine market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Recombinant Influenza Vaccine market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Recombinant Influenza Vaccine market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Recombinant Influenza Vaccine market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Recombinant Influenza Vaccine market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Recombinant Influenza Vaccine market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Recombinant Influenza Vaccine, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Recombinant Influenza Vaccine market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Recombinant Influenza Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Vial
Prefilled
Market segment by Application
Public Sector
Private Sector
Global Recombinant Influenza Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Recombinant Influenza Vaccine, market overview.
Chapter 2: Global Recombinant Influenza Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of Recombinant Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Influenza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Recombinant Influenza Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Recombinant Influenza Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Recombinant Influenza Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Recombinant Influenza Vaccine Overall Market Size
2.1 Global Recombinant Influenza Vaccine Market Size: 2022 VS 2029
2.2 Global Recombinant Influenza Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Recombinant Influenza Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top Recombinant Influenza Vaccine Players in Global Market
3.2 Top Global Recombinant Influenza Vaccine Companies Ranked by Revenue
3.3 Global Recombinant Influenza Vaccine Revenue by Companies
3.4 Global Recombinant Influenza Vaccine Sales by Companies
3.5 Global Recombinant Influenza Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Recombinant Influenza Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Recombinant Influenza Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Recombinant Influenza Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Recombinant Influenza Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Recombinant Influenza Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Recombinant Influenza Vaccine Market Size Markets, 2022 & 2029
4.1.2 Vial
4.1.3 Prefilled
4.2 By Type – Global Recombinant Influenza Vaccine Revenue & Forecasts
4.2.1 By Type – Global Recombinant Influenza Vaccine Revenue, 2018-2023
4.2.2 By Type – Global Recombinant Influenza Vaccine Revenue, 2024-2029
4.2.3 By Type – Global Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
4.3 By Type – Global Recombinant Influenza Vaccine Sales & Forecasts
4.3.1 By Type – Global Recombinant Influenza Vaccine Sales, 2018-2023
4.3.2 By Type – Global Recombinant Influenza Vaccine Sales, 2024-2029
4.3.3 By Type – Global Recombinant Influenza Vaccine Sales Market Share, 2018-2029
4.4 By Type – Global Recombinant Influenza Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Recombinant Influenza Vaccine Market Size, 2022 & 2029
5.1.2 Public Sector
5.1.3 Private Sector
5.2 By Application – Global Recombinant Influenza Vaccine Revenue & Forecasts
5.2.1 By Application – Global Recombinant Influenza Vaccine Revenue, 2018-2023
5.2.2 By Application – Global Recombinant Influenza Vaccine Revenue, 2024-2029
5.2.3 By Application – Global Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
5.3 By Application – Global Recombinant Influenza Vaccine Sales & Forecasts
5.3.1 By Application – Global Recombinant Influenza Vaccine Sales, 2018-2023
5.3.2 By Application – Global Recombinant Influenza Vaccine Sales, 2024-2029
5.3.3 By Application – Global Recombinant Influenza Vaccine Sales Market Share, 2018-2029
5.4 By Application – Global Recombinant Influenza Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Recombinant Influenza Vaccine Market Size, 2022 & 2029
6.2 By Region – Global Recombinant Influenza Vaccine Revenue & Forecasts
6.2.1 By Region – Global Recombinant Influenza Vaccine Revenue, 2018-2023
6.2.2 By Region – Global Recombinant Influenza Vaccine Revenue, 2024-2029
6.2.3 By Region – Global Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
6.3 By Region – Global Recombinant Influenza Vaccine Sales & Forecasts
6.3.1 By Region – Global Recombinant Influenza Vaccine Sales, 2018-2023
6.3.2 By Region – Global Recombinant Influenza Vaccine Sales, 2024-2029
6.3.3 By Region – Global Recombinant Influenza Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Recombinant Influenza Vaccine Revenue, 2018-2029
6.4.2 By Country – North America Recombinant Influenza Vaccine Sales, 2018-2029
6.4.3 US Recombinant Influenza Vaccine Market Size, 2018-2029
6.4.4 Canada Recombinant Influenza Vaccine Market Size, 2018-2029
6.4.5 Mexico Recombinant Influenza Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Recombinant Influenza Vaccine Revenue, 2018-2029
6.5.2 By Country – Europe Recombinant Influenza Vaccine Sales, 2018-2029
6.5.3 Germany Recombinant Influenza Vaccine Market Size, 2018-2029
6.5.4 France Recombinant Influenza Vaccine Market Size, 2018-2029
6.5.5 U.K. Recombinant Influenza Vaccine Market Size, 2018-2029
6.5.6 Italy Recombinant Influenza Vaccine Market Size, 2018-2029
6.5.7 Russia Recombinant Influenza Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries Recombinant Influenza Vaccine Market Size, 2018-2029
6.5.9 Benelux Recombinant Influenza Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Recombinant Influenza Vaccine Revenue, 2018-2029
6.6.2 By Region – Asia Recombinant Influenza Vaccine Sales, 2018-2029
6.6.3 China Recombinant Influenza Vaccine Market Size, 2018-2029
6.6.4 Japan Recombinant Influenza Vaccine Market Size, 2018-2029
6.6.5 South Korea Recombinant Influenza Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia Recombinant Influenza Vaccine Market Size, 2018-2029
6.6.7 India Recombinant Influenza Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Recombinant Influenza Vaccine Revenue, 2018-2029
6.7.2 By Country – South America Recombinant Influenza Vaccine Sales, 2018-2029
6.7.3 Brazil Recombinant Influenza Vaccine Market Size, 2018-2029
6.7.4 Argentina Recombinant Influenza Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Recombinant Influenza Vaccine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Recombinant Influenza Vaccine Sales, 2018-2029
6.8.3 Turkey Recombinant Influenza Vaccine Market Size, 2018-2029
6.8.4 Israel Recombinant Influenza Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia Recombinant Influenza Vaccine Market Size, 2018-2029
6.8.6 UAE Recombinant Influenza Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi
7.1.1 Sanofi Company Summary
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Recombinant Influenza Vaccine Major Product Offerings
7.1.4 Sanofi Recombinant Influenza Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Key News & Latest Developments
8 Global Recombinant Influenza Vaccine Production Capacity, Analysis
8.1 Global Recombinant Influenza Vaccine Production Capacity, 2018-2029
8.2 Recombinant Influenza Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global Recombinant Influenza Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Recombinant Influenza Vaccine Supply Chain Analysis
10.1 Recombinant Influenza Vaccine Industry Value Chain
10.2 Recombinant Influenza Vaccine Upstream Market
10.3 Recombinant Influenza Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Recombinant Influenza Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
Table 1. Key Players of Recombinant Influenza Vaccine in Global Market
Table 2. Top Recombinant Influenza Vaccine Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Recombinant Influenza Vaccine Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Recombinant Influenza Vaccine Revenue Share by Companies, 2018-2023
Table 5. Global Recombinant Influenza Vaccine Sales by Companies, (K Units), 2018-2023
Table 6. Global Recombinant Influenza Vaccine Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Recombinant Influenza Vaccine Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Recombinant Influenza Vaccine Product Type
Table 9. List of Global Tier 1 Recombinant Influenza Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Recombinant Influenza Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Recombinant Influenza Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Recombinant Influenza Vaccine Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Recombinant Influenza Vaccine Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Recombinant Influenza Vaccine Sales (K Units), 2018-2023
Table 15. By Type - Global Recombinant Influenza Vaccine Sales (K Units), 2024-2029
Table 16. By Application – Global Recombinant Influenza Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Recombinant Influenza Vaccine Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Recombinant Influenza Vaccine Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Recombinant Influenza Vaccine Sales (K Units), 2018-2023
Table 20. By Application - Global Recombinant Influenza Vaccine Sales (K Units), 2024-2029
Table 21. By Region – Global Recombinant Influenza Vaccine Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Recombinant Influenza Vaccine Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Recombinant Influenza Vaccine Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Recombinant Influenza Vaccine Sales (K Units), 2018-2023
Table 25. By Region - Global Recombinant Influenza Vaccine Sales (K Units), 2024-2029
Table 26. By Country - North America Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Recombinant Influenza Vaccine Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Recombinant Influenza Vaccine Sales, (K Units), 2018-2023
Table 29. By Country - North America Recombinant Influenza Vaccine Sales, (K Units), 2024-2029
Table 30. By Country - Europe Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Recombinant Influenza Vaccine Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Recombinant Influenza Vaccine Sales, (K Units), 2018-2023
Table 33. By Country - Europe Recombinant Influenza Vaccine Sales, (K Units), 2024-2029
Table 34. By Region - Asia Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Recombinant Influenza Vaccine Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Recombinant Influenza Vaccine Sales, (K Units), 2018-2023
Table 37. By Region - Asia Recombinant Influenza Vaccine Sales, (K Units), 2024-2029
Table 38. By Country - South America Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Recombinant Influenza Vaccine Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Recombinant Influenza Vaccine Sales, (K Units), 2018-2023
Table 41. By Country - South America Recombinant Influenza Vaccine Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Recombinant Influenza Vaccine Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Recombinant Influenza Vaccine Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Recombinant Influenza Vaccine Sales, (K Units), 2024-2029
Table 46. Sanofi Company Summary
Table 47. Sanofi Recombinant Influenza Vaccine Product Offerings
Table 48. Sanofi Recombinant Influenza Vaccine Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Sanofi Key News & Latest Developments
Table 50. Recombinant Influenza Vaccine Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 51. Global Recombinant Influenza Vaccine Capacity Market Share of Key Manufacturers, 2021-2023
Table 52. Global Recombinant Influenza Vaccine Production by Region, 2018-2023 (K Units)
Table 53. Global Recombinant Influenza Vaccine Production by Region, 2024-2029 (K Units)
Table 54. Recombinant Influenza Vaccine Market Opportunities & Trends in Global Market
Table 55. Recombinant Influenza Vaccine Market Drivers in Global Market
Table 56. Recombinant Influenza Vaccine Market Restraints in Global Market
Table 57. Recombinant Influenza Vaccine Raw Materials
Table 58. Recombinant Influenza Vaccine Raw Materials Suppliers in Global Market
Table 59. Typical Recombinant Influenza Vaccine Downstream
Table 60. Recombinant Influenza Vaccine Downstream Clients in Global Market
Table 61. Recombinant Influenza Vaccine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Recombinant Influenza Vaccine Segment by Type in 2022
Figure 2. Recombinant Influenza Vaccine Segment by Application in 2022
Figure 3. Global Recombinant Influenza Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Recombinant Influenza Vaccine Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Recombinant Influenza Vaccine Revenue, 2018-2029 (US$, Mn)
Figure 7. Recombinant Influenza Vaccine Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Recombinant Influenza Vaccine Revenue in 2022
Figure 9. By Type - Global Recombinant Influenza Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
Figure 11. By Type - Global Recombinant Influenza Vaccine Sales Market Share, 2018-2029
Figure 12. By Type - Global Recombinant Influenza Vaccine Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Recombinant Influenza Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
Figure 15. By Application - Global Recombinant Influenza Vaccine Sales Market Share, 2018-2029
Figure 16. By Application - Global Recombinant Influenza Vaccine Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Recombinant Influenza Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Recombinant Influenza Vaccine Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
Figure 20. By Region - Global Recombinant Influenza Vaccine Sales Market Share, 2018-2029
Figure 21. By Country - North America Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
Figure 22. By Country - North America Recombinant Influenza Vaccine Sales Market Share, 2018-2029
Figure 23. US Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Recombinant Influenza Vaccine Sales Market Share, 2018-2029
Figure 28. Germany Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 29. France Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Recombinant Influenza Vaccine Sales Market Share, 2018-2029
Figure 37. China Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 41. India Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
Figure 43. By Country - South America Recombinant Influenza Vaccine Sales Market Share, 2018-2029
Figure 44. Brazil Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Recombinant Influenza Vaccine Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Recombinant Influenza Vaccine Sales Market Share, 2018-2029
Figure 48. Turkey Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Recombinant Influenza Vaccine Revenue, (US$, Mn), 2018-2029
Figure 52. Global Recombinant Influenza Vaccine Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Recombinant Influenza Vaccine by Region, 2022 VS 2029
Figure 54. Recombinant Influenza Vaccine Industry Value Chain
Figure 55. Marketing Channels
• 日本語訳：世界の組換えインフルエンザワクチン市場予測2023-2029：バイアル、充填済み
• レポートコード：MRC2312MG01571 ▷ お問い合わせ（見積依頼・ご注文・質問）